
Kevin J. Tracey Receives Prestigious Double Helix Medal for Pioneering Contributions to Bioelectronic Medicine
Kevin J. Tracey, MD, widely recognized as the founding father of bioelectronic medicine and president and chief executive officer of Northwell Health’s Feinstein Institutes for Medical Research, has received the prestigious Double Helix Medal from Cold Spring Harbor Laboratory (CSHL). The award was presented on November 10 at the organization’s annual Double Helix Medals Dinner in New York City, recognizing Dr. Tracey’s decades of scientific contributions to understanding the relationship between the nervous system, the brain and the body’s immune response.
The recognition celebrates Dr. Tracey’s pioneering research into how the nervous system regulates inflammation and how this biological mechanism can be used to develop innovative treatments for diseases associated with chronic or excessive inflammatory activity. His scientific discoveries have helped establish bioelectronic medicine as an emerging field that combines neuroscience, molecular medicine and bioengineering to develop technologies capable of controlling biological processes and treating diseases through electrical stimulation.
Dr. Tracey received the honor alongside philanthropist Michael Milken, whose contributions to healthcare, medical research and philanthropy have also been recognized by the scientific community.
The Double Helix Medal is among the distinguished honors presented by Cold Spring Harbor Laboratory. It recognizes individuals whose groundbreaking discoveries have transformed biomedical research, as well as leaders who have supported scientific advancement and increased public awareness of important developments in biology and medicine.
Previous recipients include internationally recognized personalities and scientific leaders such as Muhammad Ali, Michael J. Fox, Kareem Abdul-Jabbar, Katie Couric and Marlo Thomas. The list also includes Nobel Prize laureates Jennifer Doudna, Katalin Karikó and Jim Allison, highlighting the award’s recognition of individuals whose work has made significant contributions to science, medicine, public health and society.
Dr. Tracey described receiving the Double Helix Medal as a significant honor and acknowledged the contributions of the scientific teams, industry collaborators, physicians and patients who supported the development of bioelectronic medicine.
He stated that the recognition belonged not only to him but also to his colleagues in laboratories and industry, along with the physicians and patients who were willing to explore an innovative scientific concept. He emphasized that the original scientific idea has now developed into a treatment approach and represents the beginning of further opportunities in medicine.
Landmark Discovery Established the Foundation of Bioelectronic Medicine
Dr. Tracey’s research has played a central role in establishing bioelectronic medicine as a new approach to understanding and treating inflammatory diseases.
Bioelectronic medicine is an interdisciplinary field that brings together neuroscience, molecular biology, immunology and bioengineering. Its objective is to understand how electrical signals within the nervous system influence the body’s biological functions and how these signals can be harnessed through medical devices to manage disease.
Unlike conventional pharmaceutical approaches that rely on medications to modify biological pathways, bioelectronic medicine explores the use of targeted electrical stimulation to influence specific neural circuits and regulate physiological responses.
A major milestone in Dr. Tracey’s career came in 2002, when his landmark research, published in the scientific journal Nature, revealed the mechanism known as the inflammatory reflex.
The discovery demonstrated how the vagus nerve, an important component of the autonomic nervous system, participates in regulating the body’s immune response and controlling inflammation.
The vagus nerve connects the brain with several major organs and plays an important role in regulating physiological functions, including heart rate, digestion and immune-related processes. Dr. Tracey’s research helped establish that this nerve also has a critical role in controlling inflammatory activity through neural signaling mechanisms.
The inflammatory reflex describes how neural signals can influence immune cells and regulate the production of inflammatory molecules. This mechanism provides the body with a natural pathway for controlling inflammation and maintaining physiological balance.
The discovery significantly expanded scientific understanding of the relationship between the nervous system and immune system.
It also provided the scientific foundation for developing implantable medical devices capable of stimulating specific nerve pathways to regulate inflammation.
This approach has opened new possibilities for treating chronic inflammatory diseases without relying exclusively on traditional pharmaceutical therapies.
Bioelectronic Technologies Offer New Treatment Possibilities for Inflammatory Diseases
Inflammation is an essential component of the body’s defense system. It helps protect against infections, respond to tissue injuries and initiate healing processes.
However, excessive or persistent inflammation can contribute to the development and progression of several chronic diseases. Conditions such as rheumatoid arthritis and Crohn’s disease involve abnormal inflammatory activity that can damage tissues and negatively affect patients’ quality of life.
Conventional treatments often involve medications designed to suppress or modify immune activity. Although these therapies can provide significant benefits, some patients may experience inadequate responses, adverse effects or limitations associated with long-term medication use.
Bioelectronic medicine offers a different therapeutic approach by targeting the neural pathways involved in regulating inflammation.
Through the use of specialized devices, researchers aim to deliver electrical stimulation to selected nerves, influencing the body’s natural inflammatory control mechanisms.
Dr. Tracey’s inflammatory reflex discovery helped establish the scientific rationale for this strategy. By identifying the role of the vagus nerve in controlling immune responses, his work enabled researchers and medical technology developers to investigate whether electrical stimulation could reproduce or enhance these natural regulatory mechanisms.
The resulting research has contributed to the development of implantable bioelectronic devices designed to treat inflammatory conditions.
Potential applications include rheumatoid arthritis, Crohn’s disease, sepsis and other disorders involving abnormal inflammatory responses.
The development of these technologies represents an important step toward expanding treatment options beyond conventional drug-based approaches.
Research Inspired FDA Approval of SetPoint Medical Device for Rheumatoid Arthritis
One of the most significant clinical developments associated with Dr. Tracey’s research is the development of the SetPoint Medical bioelectronic therapy for rheumatoid arthritis.
His foundational research on the inflammatory reflex directly inspired the development of this technology, which received U.S. Food and Drug Administration (FDA) approval in 2025.
The SetPoint Medical system represents a major milestone in translating discoveries about neural regulation of inflammation into a clinical treatment.
It is the first non-pharmacologic bioelectronic therapy approved for rheumatoid arthritis, demonstrating how fundamental scientific research can lead to new treatment technologies for patients with chronic inflammatory diseases.
The device is designed to use electrical stimulation to influence the body’s inflammatory response through targeted neural pathways.
Rheumatoid arthritis is a chronic autoimmune disease characterized by persistent inflammation that can affect the joints, resulting in pain, swelling, stiffness and progressive joint damage.
Although several pharmaceutical treatments are available, some patients continue to experience inadequate disease control or face challenges with existing treatment approaches.
Bioelectronic stimulation provides an alternative therapeutic strategy by targeting the neural mechanisms involved in controlling inflammation.
The FDA approval of the SetPoint Medical device represents an important example of the clinical translation of bioelectronic medicine, demonstrating the potential of device-based interventions in conditions traditionally managed through pharmaceutical therapies.
Northwell Health also played an important role in bringing this technology into clinical practice. The healthcare system became the first health system in the United States to implant the SetPoint System for patients with rheumatoid arthritis.
This milestone reflects the organization’s involvement in advancing innovative medical technologies and expanding access to emerging treatment approaches.
The development and clinical introduction of the SetPoint System illustrate the progression of Dr. Tracey’s scientific discovery from laboratory research to an approved medical technology.
Feinstein Institutes Expand Their Role as a Global Center for Bioelectronic Medicine
Under Dr. Tracey’s leadership, the Feinstein Institutes for Medical Research have developed into a major international research center dedicated to bioelectronic medicine and innovative biomedical technologies.
The research organization operates under Northwell Health and focuses on advancing scientific discoveries that can improve the prevention, diagnosis and treatment of diseases.
Today, the Feinstein Institutes encompass six research institutes and more than 50 laboratories, supported by approximately 5,000 researchers and staff.
The organization brings together scientists, physicians, engineers and other specialists working across multiple areas of biomedical research.
Its scientific programs cover a broad range of disciplines, including neuroscience, immunology, molecular medicine, bioengineering and translational research.
By combining expertise across these areas, the Feinstein Institutes aim to accelerate the development of technologies and treatments that can address significant unmet medical needs.
Bioelectronic medicine remains one of the organization’s central research priorities.
The institute’s work includes investigating the neural pathways involved in regulating inflammation, developing technologies for targeted nerve stimulation and translating laboratory discoveries into clinical applications.
The organization’s research infrastructure also supports collaborations between academic researchers, healthcare professionals and biotechnology and medical device companies.
These partnerships are important for advancing emerging technologies from early scientific investigation toward clinical evaluation and eventual patient access.
Northwell Health Leadership Recognizes Dr. Tracey’s Scientific Contributions
John D’Angelo, MD, president and chief executive officer of Northwell Health, congratulated Dr. Tracey on receiving the Double Helix Medal and highlighted the importance of sustained investment in medical research.
D’Angelo described the recognition as a well-deserved acknowledgment of Dr. Tracey’s scientific contributions and the long-term commitment required to translate innovative discoveries into clinical treatments.
He emphasized that the discovery of the inflammatory reflex established an entirely new field of medicine and is now contributing to treatment approaches that can make a meaningful difference in patients’ lives.
According to D’Angelo, Dr. Tracey’s achievements demonstrate the importance of supporting scientific research that challenges conventional approaches and expands the possibilities of modern medicine.
Northwell Health has continued to invest in research programs that bring together scientific innovation and clinical care.
The organization’s support for the Feinstein Institutes has helped establish an environment in which researchers can investigate new therapeutic approaches, develop medical technologies and collaborate with clinicians to advance patient care.
The recognition from Cold Spring Harbor Laboratory also highlights the broader impact of Northwell Health’s research strategy and its commitment to advancing biomedical innovation.
Dr. Tracey Receives Additional International Scientific Recognition
The Double Helix Medal adds to a series of honors recognizing Dr. Tracey’s contributions to biomedical research, engineering and medical innovation.
In 2026, he was named an Innovator on TIME magazine’s TIME100 Health list, which recognizes influential individuals contributing to healthcare and medical advancement.
The recognition reflects his role in establishing bioelectronic medicine and translating discoveries about the nervous system and immune regulation into innovative treatment technologies.
Dr. Tracey was also elected as a Fellow of the Royal Swedish Academy of Engineering Sciences, one of Sweden’s prominent distinctions recognizing achievements in engineering and scientific research.
In addition, he was inducted into the National Academy of Inventors (NAI) Class of 2025 as a Fellow.
The National Academy of Inventors Fellowship is considered its highest professional distinction and recognizes inventors whose work has contributed to technological advancement and innovation.
Dr. Tracey’s induction specifically recognized his discovery of the inflammatory reflex and his contributions to founding the field of bioelectronic medicine.
These distinctions reflect the growing scientific and clinical recognition of bioelectronic approaches as an important area of medical innovation.
Feinstein Institutes Research Achievements Receive Global Recognition
The Feinstein Institutes have also received institutional recognition for their contributions to scientific and technological advancement.
Among the notable achievements is the development of the double neural bypass, an innovative research initiative involving neural interfaces designed to restore movement and function in individuals with paralysis.
The technology was recognized by TIME magazine as one of its Best Inventions of 2024 and was subsequently included in TIME’s Hall of Fame.
The double neural bypass research demonstrates the potential of advanced neurotechnology to establish communication pathways between the brain and the body, potentially helping individuals regain control over movements affected by neurological injuries.
The recognition highlights the breadth of research conducted at the Feinstein Institutes beyond inflammatory disease and bioelectronic medicine.
Northwell Health also received recognition through its inclusion on TIME100’s Most Influential Companies list for 2025.
These achievements demonstrate the organization’s broader role in advancing healthcare innovation, medical research and technologies designed to address complex clinical challenges.
Author of The Great Nerve Highlights the Science of the Vagus Nerve
In addition to his scientific research and institutional leadership, Dr. Tracey has contributed to public understanding of bioelectronic medicine through his book, The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes.
The book explores the scientific importance of the vagus nerve and its role in regulating physiological processes, particularly the body’s inflammatory response.
It also explains how advances in neuroscience and immunology are creating new opportunities to understand the relationship between the brain, nervous system and immune system.
Through the publication, Dr. Tracey aims to make complex scientific concepts more accessible to readers and explain how discoveries in neural regulation could influence the future of medical treatment.
His work as an author complements his research and leadership activities by increasing awareness of the potential applications of bioelectronic medicine among patients, healthcare professionals and the general public.
Cold Spring Harbor Laboratory Recognizes Transformative Scientific Contributions
Founded in 1890, Cold Spring Harbor Laboratory is internationally recognized for its contributions to molecular biology and biomedical research.
The institution has been associated with eight Nobel Prize winners and is widely regarded as one of the influential centers of scientific discovery.
Its research programs have contributed to advances in genetics, molecular biology, cancer research, neuroscience and other areas of biomedical science.
The journal Nature has recognized Cold Spring Harbor Laboratory as a leading academic research institution for scientific impact, describing it as a hub of scientific breakthroughs.
The annual Double Helix Medals Dinner brings together prominent leaders from science, medicine, business and philanthropy to recognize individuals whose work has advanced human health and biological research.
This year’s event attracted more than 450 attendees, including representatives from scientific institutions, healthcare organizations and philanthropic communities.
The presentation of the Double Helix Medal to Dr. Tracey recognizes the importance of his contributions to understanding the biological connection between the nervous system and inflammation.
His discovery of the inflammatory reflex has established the scientific foundation for a new therapeutic discipline, with applications extending from chronic inflammatory diseases to emerging bioelectronic technologies.
As research continues to advance, bioelectronic medicine may create additional opportunities to develop targeted, device-based treatments for conditions that have traditionally relied on pharmaceutical interventions.
Dr. Tracey’s recognition underscores the growing importance of interdisciplinary research and the translation of fundamental scientific discoveries into practical medical solutions.
For more information about Dr. Kevin J. Tracey and the Feinstein Institutes for Medical Research, visit Northwell Health’s Feinstein Institutes.
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research.
We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program.


